HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GSK2795039

an NADPH oxidase 2 inhibitor; structure in first source

Also Known As:

N-(1-isopropyl-3-(1-methylindolin-6-yl)-1H-pyrrolo(2,3-b)pyridin-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Networked: 8 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	He, Ruixing: 1 article (01/2022)
2.	Lin, Lihui: 1 article (01/2022)
3.	Ren, Jiangbin: 1 article (01/2022)
4.	Sun, Kun: 1 article (01/2022)
5.	Wang, Weijie: 1 article (01/2022)
6.	Zhang, Xiaotian: 1 article (01/2022)
7.	Bai, Shuang: 1 article (08/2021)
8.	Deng, Hong: 1 article (08/2021)
9.	Guo, Guang-Yu: 1 article (08/2021)
10.	Guo, Wen-Liang: 1 article (08/2021)

Related Diseases

1.	Inflammation (Inflammations) 08/10/2015 - "Following systemic administration in mice, GSK2795039 abolished the production of ROS by activated NOX2 enzyme in a paw inflammation model. " 12/30/2022 - "Our results showed that treatment with GSK2795039 improved the dysfunctional voiding behavior induced by CYP, reduced bladder edema and inflammation, and preserved the urothelial barrier integrity and tight junction occludin expression, besides inhibiting the characteristic vesical pain and bladder superoxide anion generation. "
2.	Pain (Aches) 12/30/2022 - "Our results showed that treatment with GSK2795039 improved the dysfunctional voiding behavior induced by CYP, reduced bladder edema and inflammation, and preserved the urothelial barrier integrity and tight junction occludin expression, besides inhibiting the characteristic vesical pain and bladder superoxide anion generation. "
3.	Necrosis 01/01/2023 - "Similarly, in DOX-treated cardiomyocytes, GSK2795039 improved cell viability, attenuated apoptosis and necrosis and prevented the increases in p-RIP1, p-RIP3 and p-MLKL expression. "
4.	Edema (Dropsy) 12/30/2022 - "Our results showed that treatment with GSK2795039 improved the dysfunctional voiding behavior induced by CYP, reduced bladder edema and inflammation, and preserved the urothelial barrier integrity and tight junction occludin expression, besides inhibiting the characteristic vesical pain and bladder superoxide anion generation. "
5.	Heart Failure 01/01/2023 - "In conclusion, GSK2795039 prevents RIP1-RIP3-MLKL-mediated cardiomyocyte necroptosis through inhibition of NADPH oxidase-derived oxidative stress, leading to the improvement of myocardial remodeling and function in DOX-induced heart failure. " 01/01/2023 - "GSK2795039 prevents RIP1-RIP3-MLKL-mediated cardiomyocyte necroptosis in doxorubicin-induced heart failure through inhibition of NADPH oxidase-derived oxidative stress." 01/01/2023 - "In this study, we investigated whether GSK2795039 prevents receptor-interacting protein kinase 1 (RIP1)-RIP3-mixed lineage kinase domain-like protein (MLKL)-mediated cardiomyocyte necroptosis in DOX-induced heart failure through NADPH oxidase inhibition. "

Related Drugs and Biologics

1.	Occludin
2.	Superoxides (Superoxide)
3.	NADPH Oxidases (NAD(P)H oxidase)
4.	Protein Isoforms (Isoforms)
5.	Proteins (Proteins, Gene)
6.	Protein Kinases (Protein Kinase)
7.	Phosphotransferases (Kinase)
8.	Cyclophosphamide (Cytoxan)
9.	setanaxib
10.	IP 24